Argos Therapeutics Inc. (NASDAQ:ARGS) shares traded up 2.9% on Wednesday . The stock traded as high as $4.99 and last traded at $4.92, with a volume of 177,163 shares changing hands. The stock had previously closed at $4.78.

Several research analysts recently weighed in on the company. FBR & Co reiterated a “buy” rating on shares of Argos Therapeutics in a research report on Saturday, May 14th. Zacks Investment Research upgraded Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Monday, August 15th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Friday, June 17th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Monday, June 20th. Eight equities research analysts have rated the stock with a buy rating, Argos Therapeutics presently has an average rating of “Buy” and an average price target of $11.50.

The company’s 50 day moving average is $5.26 and its 200 day moving average is $5.93. The firm’s market cap is $202.28 million.

Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.05. On average, equities research analysts anticipate that Argos Therapeutics Inc. will post ($1.49) EPS for the current year.

In other news, major shareholder International S. Pharmstandard bought 67,371 shares of the firm’s stock in a transaction that occurred on Wednesday, August 24th. The stock was purchased at an average cost of $4.52 per share, with a total value of $304,516.92. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder International S. Pharmstandard bought 75,474 shares of the firm’s stock in a transaction that occurred on Monday, August 22nd. The stock was purchased at an average cost of $4.24 per share, with a total value of $320,009.76. The disclosure for this purchase can be found here.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.